These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 15357870)

  • 1. Contrast echocardiography: evidence for clinical use.
    Bhatia VK; Senior R
    J Am Soc Echocardiogr; 2008 May; 21(5):409-16. PubMed ID: 18329848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second-generation echocardiographic contrast agent capable of producing myocardial opacification from a venous injection.
    Skyba DM; Camarano G; Goodman NC; Price RJ; Skalak TC; Kaul S
    J Am Coll Cardiol; 1996 Nov; 28(5):1292-300. PubMed ID: 8890829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients).
    Main ML; Ryan AC; Davis TE; Albano MP; Kusnetzky LL; Hibberd M
    Am J Cardiol; 2008 Dec; 102(12):1742-6. PubMed ID: 19064035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse reactions to ultrasound contrast agents: is the risk worth the benefit?
    Dijkmans PA; Visser CA; Kamp O
    Eur J Echocardiogr; 2005 Oct; 6(5):363-6. PubMed ID: 16153557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].
    Vogl TJ; Friebe CE; Balzer T; Mack MG; Steiner S; Schedel H; Pegios W; Lanksch W; Banzer D; Felix R
    Radiologe; 1995 Aug; 35(8):508-16. PubMed ID: 7568795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of intravenous application of second-generation ultrasound contrast agent in children: prospective analysis.
    Piskunowicz M; Kosiak W; Batko T; Piankowski A; Połczyńska K; Adamkiewicz-Drożyńska E
    Ultrasound Med Biol; 2015 Apr; 41(4):1095-9. PubMed ID: 25701526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
    Herborn CU; Jäger-Booth I; Lodemann KP; Spinazzi A; Goyen M
    Rofo; 2009 Jul; 181(7):652-7. PubMed ID: 19291607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trials of MRX-115. A new ultrasound contrast agent.
    Fritz TA; Unger EC; Sutherland G; Sahn D
    Invest Radiol; 1997 Dec; 32(12):735-40. PubMed ID: 9406013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological characterization of microlesions induced by myocardial contrast echocardiography.
    Miller DL; Li P; Gordon D; Armstrong WF
    Echocardiography; 2005 Jan; 22(1):25-34. PubMed ID: 15660683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts.
    Parker JM; Weller MW; Feinstein LM; Adams RJ; Main ML; Grayburn PA; Cosgrove DO; Goldberg BA; Darge K; Nihoyannopoulos P; Wilson S; Monaghan M; Piscaglia F; Fowlkes B; Mathias W; Moriyasu F; Chammas MC; Greenbaum L; Feinstein SB
    Am J Cardiol; 2013 Oct; 112(7):1039-45. PubMed ID: 23816393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the safety and clinical utility of contrast echocardiography.
    Chai SC; Tan PJ; Tong KL
    Singapore Med J; 2020 Apr; 61(4):181-183. PubMed ID: 31820006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood-pool enhancement with SH U 508 A. Results of phase II clinical trials.
    Schlief R; Schürmann R; Niendorf HP
    Invest Radiol; 1991 Nov; 26 Suppl 1():S188-9; discussion S198-200. PubMed ID: 1808124
    [No Abstract]   [Full Text] [Related]  

  • 13. Does contrast echocardiography induce increases in markers of myocardial necrosis, inflammation and oxidative stress suggesting myocardial injury?
    Knebel F; Schimke I; Eddicks S; Walde T; Ziebig R; Schattke S; Baumann G; Borges AC
    Cardiovasc Ultrasound; 2005 Aug; 3():21. PubMed ID: 16107209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological evaluation of the new stable ultrasound contrast agent LK565: a phase one clinical trial.
    Funke B; Maerz HK; Okorokow S; Polata S; Lehmann I; Sack U; Wild P; Geisler T; Zotz RJ
    Cardiovasc Ultrasound; 2004 Sep; 2():16. PubMed ID: 15357870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Freehand three-dimensional assessment of left ventricular volumes and ejection fraction with ultrasound contrast agent LK565.
    Geisler T; Rost HC; Wild PS; Zotz R
    Eur J Echocardiogr; 2007 Jan; 8(1):19-29. PubMed ID: 16678491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety and efficacy of LK565--a new polymer ultrasound contrast medium].
    Zotz RJ; Schenk S; Kuhn A; Schlünken S; Krone V; Bruns W; Genth S; Schuler G
    Z Kardiol; 2001 Jun; 90(6):419-26. PubMed ID: 11486577
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.